| Evaluation Time | Study Treatment | Baseline Values* | Values at Each Time Point | Delta at Each Time Point |
|---|---|---|---|---|
| Total Cholesterol | ||||
| Baseline | Placebo (n=70) | 224 (40) | - | - |
| CGS (n=91) | 219 (32) | - | - | |
| Year 1 | Placebo (n=56) | 226 (40) | 221 (48) | -5 (41) |
| CGS (n=77) | 219 (33) | 223 (33) | 4 (33) | |
| Year 2 | Placebo (n=47) | 220 (37) | 225 (37) | 4 (37) |
| CGS (n=66) | 219 (32) | 222 (35) | 3 (31) | |
| Year 3 | Placebo (n=36) | 220 (38) | 221 (38) | 1 (35) |
| CGS (n=62) | 216 (30) | 216 (35) | 0 (37) | |
| LDL Cholesterol | ||||
| Baseline | Placebo (n=70) | 154 (41) | - | - |
| CGS (n=92) | 161 (34) | - | - | |
| Year 1 | Placebo (n=56) | 155 (40) | 153 (39) | -2 (33) |
| CGS (n=78) | 161 (34) | 159 (36) | -3 (32) | |
| Year 2 | Placebo (n=47) | 147 (36) | 148 (36) | 1 (32) |
| CGS (n=66) | 161 (33) | 161 (35) | -1 (24) | |
| Year 3 | Placebo (n=36) | 147 (38) | 140 (34) | -7 (31) |
| CGS (n=63) | 157 (29) | 153 (34) | -5 (31) | |